Nantilus, December 15th, 2017, Nantes


Program


9.00   Welcome coffee

9.15     Welcome speech

 

9.30    Special Opening Session

John Schiller, National Cancer Institute,NIH, Bethesda, US

HPV VLP Vaccines: Moving Toward a Single Dose

 

10.15    Coffee break

 

Session 1: Oncogenic mechanisms - Viroinduction

10.30    Michaël Herfs, University of Liege, Belgium

Viral carcinogenesis: from molecular mechanisms to hepatocellular, cervical, anal and head and neck cancers

11.00    Antoine Touzé, University of Tours, France

Merkel cell polyomavirus and Merkel cell carcinoma

11.20    Sylvie Hermouet, CRCINA, University of Nantes, France

Monoclonal Ig in monoclonal gammopathies of undetermined significance (MGUS) and in multiple myeloma target infectious pathogens

11.40   Vincent Larochette, CRCINA, Inserm, Angers, France

IL-26 inhibits Hepatitis C virus replication in hepatocytes

11.50    Discussion

 

12.00    Lunch

Posters & industrials partners visit

 

Session 2: Diagnostic and epidemiology

13.30     Catherine de Martel, International Agency for Research on Cancer, Lyon, France

The unequal burden of cancer attributable to infections across the world

14.00    Tarik Gheit, International Agency for Research on Cancer, Lyon, France

The IARC platform for detection of a broad spectrum of infectious agents

14.20    Janet Hall, Centre Recherche en Cancérologie, Lyon

Association between Hepatitis B virus Pre-S2 deletion and increased risk of hepatocellular carcinoma : a case-control study in West Africa

14.40    Caroline Lefeuvre, CHU, Angers, France

Urinary HPV DNA testing as a tool for cervical screening in France

 

14.50    Discussion

 

Session 3: Microbiote and cancer

15.00    Lisa Derosa, Institut Gustave Roussy, Villejuif, France

Translating bacteria into new cancer therapeutics

15.30    Richard Bonnet, CHU, Clermont-Ferrand, France

Colorectal cancer and microbiota: a focus on E. coli, an enemy within?

15.50    Laetitia Aymeric, CRCINA, Inserm, Angers, France

 

Colorectal cancer condition promotes Streptococcus gallolyticus gut colonization

16.00    Discussion

 

16.10 Coffee Break

 

Session 4: Immunotherapeutic strategies

16.30    Toos Daemen, University Medical Center Groningen (UMCG), Groningen, The Netherlands

Alphavirus-based cancer immunotherapy; efficacy, combinations and PET imaging

17.00    Jean-François Fonteneau, CRCINA, Inserm, Nantes, France

Oncolytic activity of the Schwarz vaccine strain of Measles virus against human malignant pleural mesothelioma

17.20   Alice Tison, CHU, Brest, France

Safety of Immune checkpoint inhibitors for the treatement of melanoma, bronchopulmonary and urologic neoplasms in patients with preexisting autoimmune disease

 

17.30     Discussion

 

17.40     Concluding remarks